adulto mayor, enfermedad inflamatoria intestinal, terapia biológica, Anti TNF

1. Rodríguez-D’Jesus A, Casellas F, Malagelada JR. Epidemiología de la enfermedad inflamatoria intestinal en el paciente de edad avanzada. Gastroenterol Hepatol. 2008;31(5):269-73. https://doi.org/10.1157/13119877
2. Klein A, Chowers Y, Eliakim R. Inflammatory bowel disease in the elderly. Gastrointest Tract Aged. 2013;151-80.
3. Hong SJ, Katz S. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. Therap Adv Gastroenterol. 2021;14:1-15.
4. Bonovas S, Pantavou K, Evripidou D, Bastiampillai AJ, Nikolopoulos GK, Peyrin-Biroulet L, et al. Safety of biological therapies in ulcerative colitis: an umbrella review of meta-analyses. Best Pract Res Clin Gastroenterol. 2018;32-33:43-7. https://doi.org/10.1016/j.bpg.2018.05.005
5. Tran V, Limketkai BN, Sauk JS. IBD in the elderly: management challenges and therapeutic considerations. Curr Gastroenterol Rep. 2019;21(11). https://doi.org/10.1007/s11894-019-0720-7
6. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):146-57. https://doi.org/10.1093/gerona/56.3.m146
7. Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA clinical practice update on management of inflammatory bowel disease in elderly patients: expert review. Gastroenterology. 2021;160(1):445-51. https://doi.org/10.1053/j.gastro.2020.08.060
8. Asscher VER, Waars SN, van der Meulen-de Jong AE, Stuyt RJL, Baven-Pronk AMC, van der Marel S, et al. Deficits in geriatric assessment associate with disease activity and burden in older patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022;20(5):e1006-21. https://doi.org/10.1016/j.cgh.2021.06.015
9. Juliao-Baños F, Puentes F, López R, Saffon MA, Reyes G, Parra V, et al. Characterization of inflammatory bowel disease in Colombia: results of a national register. Rev Gastroenterol Mex. 2021;86(2):153-62. https://doi.org/10.1016/j.rgmx.2020.05.005
10. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121-5.
11. U. S. Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade [internet]. FDA; 2014 [citado 2023 jul 11]. Disponible en: https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade
12. U. S. Food and Drug Administration. NDA/BLA multi-disciplinary review and evaluation BLA 125433, supplement 30 IV Golimumab (Simponi Aria) [internet]. FDA. [Citado 2023 jul 11]. Disponible en: https://www.fda.gov/media/143318/download
13. U. S. Food and Drug Administration. FDA Approves Cyltezo, the first interchangeable biosimilar to Humira: Second Interchangeable Biosimilar Product Approved by Agency [internet]. FDA; 2021 oct 18 [citado 2023 jul 11]. Disponible en: https://www.fda.gov/news-events/press-announcements/fda-approves-cyltezo-first-interchangeable-biosimilar-humira
14. De Jong ME, Smits LJT, Van Ruijven B, Den Broeder N, Russel MGVM, Römkens TEH, et al. Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients. J Crohn’s Colitis. 2020;14(7):888-95.
15. Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, et al. Persistence on anti-tumour necrosis factor therapy in older patients with inflammatory bowel disease compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Drugs Aging. 2020;37(5):383-92. https://doi.org/10.1007/s40266-020-00744-3
16. U. S. Food and Drug Administration. Drug trials snapshot: Entyvio (vedolizumab) to treat ulcerative colitis [internet]. FDA. [Citado 2023 jul 11]. Disponible en: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-entyvio-vedolizumab-treat-ulcerative-colitis
17. Mayo T, Py T, Serious D, Oi N. Abstracts [731]. 2017;112(October):2016-7.
18. Kochar B, Pate V, Kappelman MD, Long MD, Ananthakrishnan AN, Chan AT, et al. Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults. Clin Gastroenterol Hepatol [Internet]. 2021;20(6):1299-1305.e5. https://doi.org/10.1016/j.cgh.2021.08.047
19. Davis R, McParland P, Dodd S, Storey D, Probert C, Collins P, et al. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis. Eur J Gastroenterol Hepatol. 2019;31(6):661-7.
20. Verstockt B, Claeys C, De Hertogh G, Van Assche G, Wolthuis A, D’Hoore A, et al. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience. United Eur Gastroenterol J. 2019;7(9):1215-25.
21. Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310-21.
22. Paul S, Roblin X. Letter: immunogenicity of anti-TNF in elderly IBD patients. Aliment Pharmacol Ther. 2019;50(3):336.
23. Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE Study. J Crohn’s Colitis. 2021;15(10):1694-706.
24. Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep. 2020;8(4):306-11. https://doi.org/10.1093/gastro/goz041
25. Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Medvedeva E, et al. Efficacy of vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients. Inflamm Bowel Dis. 2021;(July):1-11. https://doi.org/10.1093/ibd/izab163
26. Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, et al. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Aliment Pharmacol Ther. 2020;51(9):852-60. https://doi.org/10.1111/apt.15680
27. U. S. Food and Drug Administration. Stelara (Ustekinumba) [internet]. FDA; 2019 [citado 2023 jul 11]. Disponible en: https://www.fda.gov/media/108945/download
28. Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151(9):961-9. https://doi.org/10.1001/jamadermatol.2015.0718
29. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2013;369(8):699-710.
30. U. S. Food and Drug Administration. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR) [internet]. FDA. [Citado 2023 jul 11]. Disponible en: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and
31. Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther. 2014;39(5):459-77.
32. Kochar B, Orkaby AR, Ananthakrishnan AN, Ritchie CS. Frailty in inflammatory bowel diseases: an emerging concept. Therap Adv Gastroenterol. 2021;14:1-12.
33. Segal JP, Htet HMT, Limdi J, Hayee B. How to manage IBD in the “elderly”. Frontline Gastroenterol. 2020;11(6):468-77. https://doi.org/10.1136/flgastro-2019-101218
34. Beaugerie L, Kirchgesner J. Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(3):370-9. https://doi.org/10.1016/j.cgh.2018.07.013

Vol. 64 Núm. 4 (2023)